OR WAIT null SECS
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 11, 2021.
Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a Network Meta-Analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.
Upadacitinib monotherapy was effective in inhibiting structural joint damage progression in patients with rheumatoid arthritis who were MTX-naïve or had an inadequate response to MTX.
“Food insecurity may increase an individual’s dependence on inexpensive energy-dense foods that lead to the development of chronic diseases that may affect mental health," investigators stated.
In this Q&A, corresponding author Richard A Furie, MD, discussed the findings of his study comparing obinutuzumab with placebo for the treatment of proliferative lupus nephritis in combination with standard therapies.
PsA Does Not Increase Risk of Venous Thromboembolic Events
Given the recent concerns regarding venous thromboembolic events in patients with rheumatic disease and pre-existing cardiovascular risk factors being treated with tofacitinib, investigators addressed the occurrence of VTE in patients with PsA.